Bambusae Caulis in Taeniam Applicable for Medical Indications Associated with Inflammation
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Jukyeo (竹茹; Bambusae Caulis in Taeniam: BCT) is an herbal medicine made from the inner part of the bamboo stem of Phyllostachys nigra Munro var. henonis Stapf ex Rendle or Phyllostachys bambusoides Siebold et Zuccarini. Although medical literature published in China and Korea decades ago introduced BCT as a remedy for reducing vomiting, fever, and hematemesis, decoctions containing BCT as a main herb (君藥) in Korea have been approved only for treating neurologic symptoms. Here, we discuss the anti-inflammatory function of BCT. Combined with the clinical usage of a BCT-containing decoction in treating inflammatory diseases in Japan, we raise the possibility of repurposing the BCT-containing decoctions for treating inflammatory diseases. The anti-inflammatory activity of BCT was mainly assessed by using RAW 264.7 cells. The regulation of NF-κB, Nrf2 and A20 activities was determined by western blot and quantitative RT-PCR. The list of decoctions containing BCT currently approved in Korea was obtained from the Korean Ministry of Food and Drug Safety (KFDA). BCT suppressed the activity of pro-inflammatory factor NF-κB elicited by LPS, activated an anti-inflammatory factor Nrf2, and induced A20 that is known to block several inflammatory pathways simultaneously, suggesting that BCT can suppress inflammation via at least 3 different pathways. KFDA approved 11 decoctions containing BCT as a major herb, including Gamiondam-tang (加味溫膽湯; GOT), for treating neurologic disorders. Interestingly, Jukyeoondam-tang (竹茹溫膽湯; JOT), whose composition is almost identical to GOT except for one herb, has been used to treat inflammatory pulmonary disorders including Covid-19 pulmonary infection in Japan Given the anti-inflammatory function of BCT evidenced by medical literature and experimental results and the clinical usage of JOT in treating inflammatory pulmonary disorders, we suggest a repurposing and extension of the BCT-containing decoctions approved in Korea to treating inflammatory diseases.
Abstract
Jukyeo (竹茹; Bambusae Caulis in Taeniam: BCT) is an herbal medicine made from the inner part of the bamboo stem of Phyllostachys nigra Munro var. henonis Stapf ex Rendle or Phyllostachys bambusoides Siebold et Zuccarini. Although medical literature published in China and Korea decades ago introduced BCT as a remedy for reducing vomiting, fever, and hematemesis, decoctions containing BCT as a main herb (君藥) in Korea have been approved only for treating neurologic symptoms. Here, we discuss the anti-inflammatory function of BCT. Combined with the clinical usage of a BCT-containing decoction in treating inflammatory diseases in Japan, we raise the possibility of repurposing the BCT-containing decoctions for treating inflammatory diseases. The anti-inflammatory activity of BCT was mainly assessed by using RAW 264.7 cells. The regulation of NF-κB, Nrf2 and A20 activities was determined by western blot and quantitative RT-PCR. The list of decoctions containing BCT currently approved in Korea was obtained from the Korean Ministry of Food and Drug Safety (KFDA). BCT suppressed the activity of pro-inflammatory factor NF-κB elicited by LPS, activated an anti-inflammatory factor Nrf2, and induced A20 that is known to block several inflammatory pathways simultaneously, suggesting that BCT can suppress inflammation via at least 3 different pathways. KFDA approved 11 decoctions containing BCT as a major herb, including Gamiondam-tang (加味溫膽湯; GOT), for treating neurologic disorders. Interestingly, Jukyeoondam-tang (竹茹溫膽湯; JOT), whose composition is almost identical to GOT except for one herb, has been used to treat inflammatory pulmonary disorders including Covid-19 pulmonary infection in Japan Given the anti-inflammatory function of BCT evidenced by medical literature and experimental results and the clinical usage of JOT in treating inflammatory pulmonary disorders, we suggest a repurposing and extension of the BCT-containing decoctions approved in Korea to treating inflammatory diseases.
참고문헌 (31)
- Kim J-H, "An literature study on Bambusae Caulis in Taeniam", Journal of the Korea Institute of Oriental Medical Informatics, 13(1), pp.55~62 (2007)
- World Health Organization, "Regional Office for the Western P. Medicinal plants in China : a selection of 150 commonly used species", WHO Regional Office for the Western Pacific, ~ (1989)
- Jiao J, "Antihyperlipidemic and antihypertensive effect of a triterpenoid-rich extract from bamboo shavings and vasodilator effect of friedelin on phenylephrine-induced vasoconstriction in thoracic aortas of rats", Phytother Res, 21(12), pp.1135~1141 (2007)
- "Supplementary Records of Famous Physicians", pp.126~127 (1986), People's Medical Publishing House
- Heo Jun, "Supplementary and Korean Translational Records of Donguibogam" (1988), Namsan Dang
- Medzhitov R, "Origin and physiological roles of inflammation", Nature, 454(7203), pp.428~435 (2008)
- Chen JK, "Chinese Medical Herbology and Pharmacology" (2004), Art of Medicine Press
- Lim D, "Original Research: Extract of Bambusae Caulis in Taeniam inhibits cigarette smoke-induced pulmonary and intestinal inflammation", Exp Biol Med(Maywood), 242(1), pp.102~112 (2017)
- Kim W, "p-Coumaric Acid, a Major Active Compound of Bambusae Caulis in Taeniam, Suppresses Cigarette Smoke-Induced Pulmonary Inflammation", Am J Chin Med, 46(2), pp.407~421 (2018)
- McInnes IB, "The pathogenesis of rheumatoid arthritis", N Engl J Med, 365(23), pp.2205~2219 (2011)
- Giannini D, "One year in review 2020: pathogenesis of rheumatoid arthritis", Clin Exp Rheumatol, 38(3), pp.387~397 (2020)
- Wang X, "Effects and relationship of ERK1 and ERK2 in interleukin-1β-induced alterations in MMP3, MMP13, type II collagen and aggrecan expression in human chondrocytes", ~
- Ra J, "Reduction of interleukin-1β induced matrix metalloproteinase-3 release by extracts of six plants: inhibitory screening of 35 traditional medicinal plants", Immunopharmacol Immunotoxicol, 33(3), pp.461~465 (2011)
- Qi XF, "Effects of Bambusae caulis in Liquamen on the development of atopic dermatitis-like skin lesions in hairless mice", J Ethnopharmacol, 123(2), pp.195~200 (2009)
- Sorriento D, "Inflammation and Cardiovascular Diseases: The Most Recent Findings", Int J Mol Sci, 20(16) (2019)
- Zhang Q, "30 Years of NF-kappaB: A Blossoming of Relevance to Human Pathobiology", Cell, 168(1-2), pp.37~57 (2017)
- Rothschild DE, "Modulating inflammation through the negative regulation of NF-kappaB signaling", J Leukoc Biol (2018)
- Jin GH, "Anti-inflammatory activity of Bambusae Caulis in Taeniam through heme oxygenase-1 expression via Nrf-2 and p38 MAPK signaling in macrophages", Environ Toxicol Pharmacol, 34(2), pp.315~323 (2012)
- Eom HW, "Bambusae Caulis in Taeniam modulates neuroprotective and anti-neuroinflammatory effects in hippocampal and microglial cells via HO-1- and Nrf-2-mediated pathways", Int J Mol Med, 30(6), pp.1512~1520 (2012)
- Bellezza I, "Nrf2-Keap1 signaling in oxidative and reductive stress", Biochim Biophys Acta Mol Cell Res, 1865(5), pp.721~733 (2018)
- Chan K, "Nrf2 is essential for protection against acute pulmonary injury in mice", ProcNatlAcadSciUSA, 96(22), pp.12731~12736 (1999)
- Boutten A, "NRF2 targeting: a promising therapeutic strategy in chronic obstructive pulmonary disease", Trends in molecular medicine, 17(7), pp.363~371 (2011)
- Rangasamy T, "Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice", JExpMed, 202(1), pp.47~59 (2005)
- Thimmulappa RK, "Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis 23", JClinInvest, 116(4), pp.984~995 (2006)
- Momtazi G, "Regulators of A20 (TNFAIP3): new drug-able targets in inflammation", Am J Physiol Lung Cell Mol Physiol, 316(3) (2019)
- Hijikata Y, "Kampo medicine, based on traditional medicine theory, in treating uncured glossodynia: efficacy in five clinical cases", Am J Chin Med, 36(5), pp.835~847 (2008)
- Gong Tingxian, "Man-Byeong-Hoi-Chun" (1998), People's Medical Publishing House
- Uematsu J, "Inhibitory effect of traditional herbal (kampo) medicines on the replication of human parainfluenza virus type 2 in vitro", Drug Discov Ther, 15(4), pp.180~188 (2021)
- Takayama S, "Prevention and Recovery of COVID-19 Patients With Kampo Medicine: Review of Case Reports and Ongoing Clinical Trials", Front Pharmacol, 12, pp.656246~ (2021)
- Sobhani Z, "Therapeutic Effects of Ziziphus jujuba Mill. Fruit in Traditional and Modern Medicine: A Review", Med Chem, 16(8), pp.1069~1088 (2020)
- Choi YY, "Inhibitory effect of Coptis chinensis on inflammation in LPS-induced endotoxemia", J Ethnopharmacol, 149(2), pp.506~512 (2013)